Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.69 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.69 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.62 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31752875 | 0.91 | CYP4A11 (0.69) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL31753372 | 0.90 | CYP4A11 (0.72) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL70173 | 0.87 | CYP4F2 (0.83) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL4878614 | 0.86 | CYP4F2 (0.68) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL697890 | 0.85 | LOXL2 (0.68) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL4081963 | 0.85 | CYP4F2 (0.68) | CYP4F2CYP4A11ALDH1A1HPGDMAPT | |
| SCHEMBL22887349 | 0.85 | CYP4F2 (0.66) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL13681361 | 0.84 | CYP4F2 (0.49) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 | |
| SCHEMBL13680789 | 0.84 | ERN1 (0.50) | CYP4F2CYP4A11LOXL2ALDH1A1MAPT | |
| SCHEMBL13685985 | 0.83 | CYP4A11 (0.46) | CYP4F2CYP4A11LOXL2SLC7A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-0235452-B1 | ORGANIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | LILLY INDUSTRIES LIMITED (GB) | 1992-03-18 | — | — | EP | disclosed |
| US-4845110-A | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1989-07-04 | — | — | US | disclosed |
| EP-0235452-A2 | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM3B | CYP4F2 3030/4885CYP4A11 2339/4885LOXL2 1533/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | CYP4F2 3030/4885CYP4A11 2339/4885LOXL2 1533/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | CYP4F2 3030/4885CYP4A11 2339/4885LOXL2 1533/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | CYP4F2 3030/4885CYP4A11 2339/4885LOXL2 1533/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | CYP4F2 3030/4885CYP4A11 2339/4885LOXL2 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.